Showing posts with label Positive. Show all posts
Showing posts with label Positive. Show all posts

Sunday, April 10, 2011

InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Cataract Surgery

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8758.

Main Category: Eye Health / Blindness
Also Included In: Pain / Anesthetics
Article Date: 23 Mar 2011 - 9:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
InSite Vision Incorporated (OTCBB:INSV) announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. This randomized four-arm study compared once- and twice-daily doses of ISV-303 versus Xibrom™ and DuraSite® (vehicle), each administered twice-daily. ISV-303 combines a lower dose (0.075%) of the non-steroidal anti-inflammatory (NSAID) bromfenac (BROMDAY™/Xibrom (bromfenac ophthalmic solution) 0.09%, marketed by ISTA Pharmaceuticals) with InSite Vision's proprietary DuraSite drug delivery technology.

The Phase 1/2 clinical trial enrolled 169 patients undergoing cataract surgery. The primary endpoint of the study was the absence of cells in the anterior chamber of the eye at day 15 post surgery. Once-daily ISV-303 achieved statistically significant superiority compared to vehicle (53.3% vs. 19.0%, p=0.0016) for the primary endpoint. Further, secondary endpoints such as reduction of flare, pain and discomfort as a result of inflammation, achieved statistically significant superiority at days 8, 15 and 29 as compared with vehicle. While once-daily ISV-303 achieved a numerically superior difference in the primary endpoint versus twice-daily Xibrom (53.3% vs. 42.2%), the results did not reach statistical significance given the relatively small size of the trial. ISV-303, Xibrom and vehicle were all generally well tolerated and there were no safety concerns or serious adverse events related to any of the agents. InSite Vision intends to present a final analysis of the ISV-303 Phase 1/2 clinical trial in conjunction with a future scientific meeting.

The exploratory Phase 1/2 study was not designed to achieve statistically significant difference between the arms. Nevertheless, the results of this relatively small study comfortably demonstrate the clear efficacy and safety of once-daily ISV-303 over DuraSite in terms of a regulatory pathway, and the promise of a commercially superior once-daily NSAID for post-surgical use in the marketplace. Following final analysis, the Company plans to initiate discussions with the U.S. Food and Drug Administration (FDA) on the design of the pivotal Phase 3 program for once-daily ISV-303. The Company also plans to conduct a Phase 2 pharmacokinetic study of once-daily ISV-303 against ISTA Pharmaceutical's currently marketed once-daily NSAID, BROMDAY.

"It is a delightfully rare situation to experience such stunningly statistically significant results in an exploratory Phase 1/2 study," said Timothy Ruane, Chief Executive Officer of InSite Vision. "With the efficacy and safety profile established in this study, and potential patent protection extending to 2029, we believe once-daily ISV-303 is very well positioned to compete in the growing $300 million ophthalmic NSAID market in the United States. Importantly, the results of this study further transform InSite Vision into a late-stage company with three Phase 3 candidates that we intend to move toward approval."

InSite Vision is advancing another product candidate that utilizes a low-concentration of bromfenac enabled by DuraSite. ISV-101, a lower dose of bromfenac in DuraSite, is being developed for the treatment of dry eye disease. On January 11, 2011, InSite Vision announced it had filed an Investigational New Drug (IND) application for ISV-101 with the FDA. The Company is now positioned to initiate a dose-ranging Phase 1/2 clinical trial in 2011 to evaluate the safety and efficacy of ISV-101 when administered to patients suffering from dry eye disease. Patent protection for this drug candidate is also expected to extend into 2029. Preclinical data on the safety of ISV-303 and ISV-101 (bromfenac formulated in DuraSite) on ocular tissues have been accepted for presentation at the 2011 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1 - 5, 2011 in Fort Lauderdale, Florida.

Cataract surgery is the most frequently performed ocular surgery in the United States with more than three million procedures annually. Following surgery, anti-inflammatory eye drops are typically prescribed to reduce pain and inflammation and to enhance healing.

Dry eye disease occurs when the surface of the eye becomes compromised for various reasons, frequently involving tear-film changes. While causes of dry eye may vary, it is frequently associated with inflammation of the surface of the eye, the lacrimal gland, and/or the conjunctiva. A potentially chronic condition that can occur at any age, dry eye disease is most prevalent among the elderly. It is estimated to affect at least twenty-five million people in the U.S. alone.

About DuraSite®

InSite's DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. InSite vision is also applying DuraSite to multiple other clinical- and preclinical-stage product candidates to create a portfolio of novel ophthalmic products.

Source:
InSite Vision

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Friday, March 25, 2011

Committee For Medicinal Products For Human Use (CHMP) Issues Positive Opinion For New Contraception Offering, NOMAC-E2


Main Category: Women's Health / Gynecology
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 21 Mar 2011 - 4:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
Teva Pharmaceuticals Europe BV, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and MSD (known as Merck in the United States and Canada) (NYSE:MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2 (nomegestrol acetate 2.5 mg /17ß-estradiol 1.5 mg) an investigational monophasic combined oral contraceptive (COC) tablet indicated for the use by women to prevent pregnancy. NOMAC-E2 is a birth control pill that contains 2 steroid hormones nomegestrol acetate, a highly selective, progesterone-derived progestin and 17-beta estradiol (E2), an estrogen that is similar to the one naturally present in a woman's body. The next step for marketing authorization is review by the European Commission.

"If approved, NOMAC-E2 has the potential to expand women's choices in contraception by providing another oral contraceptive offering and is the result of a fruitful collaboration with MSD."

"We are pleased with CHMP's recommendation to approve NOMAC-E2", said Christophe Hubert, managing director of Théramex and vice-president Women's Health Teva Europe. "If approved, NOMAC-E2 has the potential to expand women's choices in contraception by providing another oral contraceptive offering and is the result of a fruitful collaboration with MSD."

"The achievement of this milestone highlights the strong collaborative relationship we have established with our colleagues at Théramex, now part of Teva," said Terrie Curran, general manager and global franchise head, Women's Health at MSD. "This underscores our ongoing commitment to developing therapies that help improve the health of women worldwide."

The CHMP issued a positive opinion following a review of comprehensive data supporting the efficacy, safety and tolerability profile of NOMAC-E2 (nomegestrol acetate/17ß-estradiol). Should marketing authorization from the European Commission be granted, it will apply to all 27 European Union (EU) Member States plus the EEA-EFTA states (Iceland, Liechtenstein and Norway).

Source:
Teva Pharmaceutical Industries Ltd.
MSD

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Tuesday, March 22, 2011

Curis Announces Positive Results In Genentech Pivotal Phase II Clinical Trial Of GDC-0449 In Advanced Basal Cell Carcinoma


Main Category: Cancer / Oncology
Also Included In: Clinical Trials / Drug Trials
Article Date: 21 Mar 2011 - 3:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced a positive outcome from a pivotal Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC). Genentech informed Curis that the study met its primary endpoint of achieving a target overall response rate, showing that GDC-0449 shrank advanced BCC tumors in a pre-defined percentage of people in the study. A preliminary safety assessment showed the most common adverse events were consistent with previous experience with vismodegib. A detailed safety assessment is ongoing. Roche has indicated that it anticipates making at least one regulatory submission in 2011 to seek approval to commercialize GDC-0449.

Genentech plans to submit the data from the clinical trial for presentation at a future medical meeting.

Roche also informed Curis that GDC-0449 (also known as RG3616) now has a generic name approved by the World Health Organization, vismodegib (pronounced vis-mo-DE-jib).

"We are extremely pleased by the highly encouraging outcome of this study, particularly since there is currently no standard of care for patients with this serious disease," said Dan Passeri, Curis President and Chief Executive Officer. "We look forward to Genentech's presentation of the study data in more detail in the near future, and to its planned regulatory submissions for vismodegib."

About the Pivotal Phase II Trial (ERIVANCE BCC/SHH4476g)

ERIVANCE BCC is an international, single-arm, multi-center, two-cohort, open-label Phase II study that enrolled 104 patients with advanced BCC, including metastatic and/or locally advanced BCC, defined as patients whose lesions are not appropriate for surgery, or for whom surgery would result in substantial deformity. Study participants received 150 mg vismodegib once daily until disease progression. The primary endpoint of the study was overall response rate (tumor shrinkage) as assessed by independent reviewers. Secondary endpoints of the study included overall response rate as assessed by study investigators, duration of response, progression-free survival, overall survival and the safety profile. A preliminary safety assessment showed the most common adverse events were muscle spasms, hair loss, altered taste sensation, weight loss, fatigue, nausea, decreased appetite and diarrhea. Serious adverse events were observed, including fatal events. The deaths are being further evaluated, but do not appear to be related to vismodegib.

About Basal Cell Carcinoma

According to the American Cancer Society, BCC is the most common type of skin cancer and accounts for approximately 80 percent of all diagnosed skin cancers. The disease is generally considered curable when the cancer is restricted to a small area of the skin. However, in a small group of people, if the disease is left untreated or does not respond to treatment, the cancer may advance further into the skin, bones or other tissues. In rare cases, BCC may advance or spread to other parts of the body, at which point the disease can become difficult to treat and life-threatening.

About Vismodegib and the Hedgehog Pathway

Vismodegib is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. However, mutations in the pathway that reactivate Hedgehog signaling are seen in several different types of cancer. Abnormal signaling in the Hedgehog pathway is implicated in the majority of BCC cases.

Genentech is also evaluating vismodegib in a Phase II trial in people with operable forms of BCC, which opened in October 2010. Additionally, vismodegib is being evaluated by third-party investigators in a number of other cancers and in people with BCC who have Gorlin syndrome. Gorlin syndrome is a condition that affects many areas of the body and increases the risk of developing BCC.

Source:
Curis, Inc.


Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here